Long-term persistence of molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia

Blood Transfusion

Volumn 10, Issue 2, 2012, Pages 233-234

  Veneri, Dino ^a   Tecchio, Cristina ^a   De Matteis, Giovanna ^a   Paviati, Elisa ^a   Benati, Marco ^a   Franchini, Massimo ^b   Pizzolo, Giovanni ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB;

ACUTE HEART INFARCTION; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; HUMAN; LETTER; LEUKEMIA REMISSION; MALE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT WITHDRAWAL;

ADULT; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; REMISSION INDUCTION; RNA, MESSENGER;

EID: 84860533241     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0057-11     Document Type: Letter

References (5)

1. Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202-7. (Pubitemid 16183150)
2. Cortes J, Hochhaus A, Hughes T, et al. Front-line and salvages therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011; 29: 524-31.
3. Mahon FX, Réa D, Guilhot J, et al Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-35.
4. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukaemia after cessation of interferon alfa. J Clin Oncol 2002; 1: 214-20. (Pubitemid 34032614)
5. Rumpold H, Webersinke G. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr Cancer Drug Targets 2010; 11: 3-19.